Laplace Interventional Inc. Announces $7.9M Series A for its Transcatheter Tricuspid Valve Technology

03 Sep, 2021

Laplace Interventional Inc. Announces $7.9M Series A for its Transcatheter Tricuspid Valve Technology
Photo by Paul Fiedler on Unsplash

– Minnesota based Laplace Interventional, a medical device company developing a transcatheter tricuspid valve technology, announced that it has closed on its Series A financing led by a non-disclosed major strategic investor along with a significant investment from ShangBay Capital, an early stage medical device investor as well as other investors.
– The $7.9M Series A financing round will fund Laplace Interventional towards achieving its preclinical milestones.
– The company also announced the addition of two Directors to its Board including William Dai, Founding Managing Partner at ShangBay Capital.
– Laplace Interventional’s device aims to offer an increase in life expectancy and an improvement to the quality of life to several patients worldwide diagnosed with Tricuspid Regurgitation (TR).

Medical Device North America
Crunchbase icon

Content report

The following text will be sent to our editors: